NAD+ and SLU-PP-332 Interaction: Synergistic | Peptide Database

Join others researching Cabergoline — share findings, ask questions, and learn from real experiences Cabergoline is a potent, long-acting dopamine D2 receptor agonist that powerfully suppresses prolactin secretion from the anterior pituitary. It is FDA-approved under the brand name Dostinex for the treatment of hyperprolactinemic disorders, including prolactin-secreting pituitary adenomas (prolactinomas). In the bodybuilding and performance enhancement community, cabergoline is considered an essential ancillary compound when running 19-nor anabolic steroids such as nandrolone (Deca-Durabolin, NPP) and trenbolone, both of which can elevate prolactin levels through progestogenic activity. Elevated prolactin causes a range of undesirable effects including gynecomastia (particularly the progesterone-mediated variant), sexual dysfunction (erectile dysfunction, decreased libido, anorgasmia), mood disturbances, and lactation. Cabergoline's exceptionally long half-life of 63-69 hours allows for convenient twice-weekly dosing, and its high affinity for D2 receptors makes it significantly more potent and better tolerated than the older dopamine agonist bromocriptine. Cabergoline exerts its effects by acting as a potent agonist at dopamine D2 receptors on lactotroph cells in the anterior pituitary gland. Prolactin secretion is tonically inhibited by hypothalamic dopamine acting on these D2 receptors, and cabergoline mimics this inhibitory signal with high affinity and prolonged duration. By activating D2 receptors, cabergoline suppresses prolactin gene transcription, reduces prolactin synthesis, and inhibits prolactin release into the bloodstream. In patients with prolactinomas, cabergoline also induces tumor shrinkage by inhibiting lactotroph cell proliferation and promoting apoptosis. The drug's selectivity for D2 receptors over D1 receptors contributes to its favorable side effect profile compared to less selective dopamine agonists. In the context of 19-nor steroid use, nandrolone and trenbolone stimulate prolactin release through their progestogenic activity, and cabergoline directly counteracts this elevation by restoring dopaminergic inhibition at the pituitary level.

Originally FDA-approved for testosterone replacement in hypogonadal men. Fluoxymesterone was used to treat delayed puberty and androgen deficiency, though it has been almost entirely replaced by injectable testosterone and transdermal preparations due to its hepatotoxicity and unfavorable side effect profile. FDA-approved for palliative treatment of androgen-responsive, advanced inoperable breast cancer in women, typically 1-5 years post-menopause. This indication is rarely used today due to the availability of aromatase inhibitors and targeted therapies with superior safety profiles. Used by powerlifters and strength athletes in the final 2-4 weeks before a competition to maximize strength output, aggression, and neural drive without adding bodyweight or water retention. The compound's effects on the central nervous system produce a pronounced increase in competitive intensity. Employed by competitive bodybuilders in the last 2-4 weeks before stage to enhance muscle hardness, vascularity, and visual density without water retention. The non-aromatizing nature ensures no subcutaneous water accumulation during the critical final phase of contest preparation. Historically used by fighters and combat sport athletes to increase aggression and power output while staying within a weight class, as it adds no water weight. This use carries significant ethical and regulatory concerns given anti-doping testing.